Celldex Therapeutics Announces Proposed Public Offering of Common Stock
HAMPTON, N.J., Feb. 28, 2024 (GLOBE NEWSWIRE) — Celldex Therapeutics, Inc. (“Celldex” or the “Company”) (Nasdaq:CLDX) today announced that it is proposing to offer and sell, subject to market conditions, $250.0 million of shares of its common stock in an underwritten public offering. Celldex expects to grant the underwriters a 30-day option to purchase up to an additional $37.5 million of shares of its common stock. All of the shares of common stock are being offered by the Company. The final terms of the offering will depend on market and other conditions at the time of pricing, and there can be no assurance as to whether or when the offering may be completed, or as to the actual size or terms of the offering.